Advertisements

Algo-Buscopan

Quick links to important sections

Algo-Buscopan

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Algo-Buscopan

Quick Facts

Property Description
Active ingredient Metamizole (Dipyrone) and Hyoscine Butylbromide
Form Tablet (Oral) and Solution (Parenteral)
Pharmacological class Combined Analgesic-Spasmolytic Agent
General purpose Symptomatic relief of Spasmodic (Visceral) Pain
Origin Synthetic Pyrazolone Derivative and Semi-synthetic Anticholinergic

Algo-Buscopan: The Definition of a Combination Drug

Algo-Buscopan is fundamentally defined as a Fixed-Dose Combination (FDC) medicinal product, containing two distinct pharmacological agents in a single preparation. This structure classifies the medicine as a combined analgesic-spasmolytic agent, intended to counteract both the painful sensation and the muscular mechanism that underlies it. This dual-component approach is what defines its core therapeutic identity, positioning it as a specialized solution for acute discomfort. The FDC approach is clinically recognized for managing conditions where pain is directly linked to smooth muscle spasms.

The Active Composition and Pharmaceutical Forms

The core composition of the drug comprises Metamizole and Hyoscine Butylbromide. Metamizole is a synthetic pyrazolone derivative known for its potent pain-relieving actions, a property characterized by its effect on peripheral pain pathways. Hyoscine Butylbromide is a semi-synthetic quaternary ammonium anticholinergic compound, which provides the targeted muscle-relaxing effect. Because this compound is poorly absorbed across the intestinal wall, its action is primarily focused on the smooth muscle lining of the digestive and urinary tracts. Algo-Buscopan is commonly manufactured in multiple dosage forms, including tablets for oral use and an aqueous solution for parenteral (injection) administration.

The General Therapeutic Rationale

The general therapeutic rationale for Algo-Buscopan is the prompt, symptomatic control of sharp, intense discomfort associated with involuntary muscle contractions, commonly referred to as spasmodic pain or visceral pain. A typical use scenario involves the acute discomfort arising from gastrointestinal or urinary tract spasms. The product’s design is based on the principle of dual action, ensuring that the muscular component of the pain is relaxed by the spasmolytic agent while the analgesic concurrently reduces the patient's sensation of the acute discomfort. This coordinated response is intended to rapidly break the cycle of acute cramping and associated pain.

Regulatory References

  1. Drugs & Supplements - MedlinePlus
Advertisements

What side effects are possible with Algo-Buscopan?

The safety profile of Algo-Buscopan, a combination of Metamizole and Hyoscine Butylbromide, is structured around the specific risks documented for each active component in governmental regulatory labeling. Officially documented adverse effects are classified by system-organ class (SOC) and frequency.

Adverse Reaction Scope

Category Description
Key adverse reaction categories Haematological disorders (e.g., Agranulocytosis), Severe Hypersensitivity (Anaphylactic Shock, SJS/TEN), Anticholinergic effects (e.g., Dry mouth, Urinary retention), and Cardiovascular reactions (Hypotension, Tachycardia).
Frequency classification Uncommon effects include tachycardia, dry mouth, and skin reactions. Rare effects include agranulocytosis and urinary retention. Very Rare effects include aplastic anaemia and severe cutaneous reactions like SJS/TEN. The frequency of Anaphylactic Shock and pancytopenia is often documented as Not Known.
Serious adverse reactions Agranulocytosis and Aplastic Anaemia are documented serious risks associated with Metamizole, which are dose-independent and can occur at any time. Anaphylactic Shock and severe cutaneous reactions are also listed as serious adverse events.

Safety Constraints and Considerations

The medicine is subject to regulatory restrictions. It is contraindicated in patients with a history of hypersensitivity to pyrazolones, pre-existing bone marrow suppression, narrow-angle glaucoma, and mechanical obstructions in the gastrointestinal tract. Safety information advises specific consideration for the elderly (due to increased anticholinergic susceptibility) and patients with hepatic or renal impairment. Use is generally advised against during the third trimester of pregnancy and lactation.

Advertisements

Overdose and Emergency Response

The regulatory profile for overdose with Algo-Buscopan (Metamizole and Hyoscine Butylbromide) describes a dual toxicity pattern, with specific guidance on emergency actions.

Documented Manifestations and Severe Outcomes

Overdosage may manifest with signs of Metamizole toxicity, including hypotension, dysrhythmia, and renal insufficiency. The anticholinergic component contributes symptoms such as tachycardia, dry mouth, urinary retention, mydriasis, and profound CNS effects (e.g., confusion, hallucinations, coma) in severe cases.

Emergency Actions and Supportive Management

Immediate medical attention must be sought if any sign of acute overdose is observed. Furthermore, if symptoms of the severe side effect agranulocytosis (fever, sore throat, mucosal sores) occur, the medicine must be stopped immediately and urgent medical assistance is required for an immediate blood count.

No specific antidote is known for Metamizole toxicity. Treatment is therefore symptomatic and supportive, focusing on measures like gastric lavage, activated charcoal, and procedural steps such as haemodialysis to accelerate drug clearance or catheterization for urinary retention. Increased susceptibility to severe anticholinergic effects is noted in elderly and children.

Advertisements

Therapeutic Uses of Algo-Buscopan

What Algo-Buscopan treats: main uses and benefits

Algo-Buscopan is a fixed-dose combination medication formulated to address specific types of abdominal discomfort. It combines an antispasmodic agent with an analgesic to provide a dual approach to symptom management.

Primary Indications

The medication is primarily used for the symptomatic relief of pain associated with spasms of the gastrointestinal tract. This includes conditions where smooth muscle contractions lead to cramping and localized distress. Common applications include:

  • Abdominal Cramps: Relief of acute pain resulting from involuntary muscle spasms in the stomach or intestines.
  • Biliary Colic: Management of discomfort associated with spasms in the bile ducts.
  • Genitourinary Spasms: Addressing pain related to spasms in the urinary tract or during menstrual cycles (dysmenorrhea).
  • Irritable Bowel Syndrome (IBS): Temporary relief of the cramping and abdominal pain often associated with functional bowel disorders.

How the Medication Works

Algo-Buscopan functions through two distinct mechanisms that work simultaneously to manage symptoms:

  1. Antispasmodic Action: The component hyoscine butylbromide targets the smooth muscles of the abdominal organs. By helping these muscles relax, it reduces the intensity and frequency of spasms, which are a primary source of cramping pain.
  2. Analgesic Action: The inclusion of paracetamol (acetaminophen) acts on the central nervous system to increase the body's pain threshold. This helps to dull the perception of pain while the antispasmodic addresses the physical cause of the contraction.

Benefits of the Combination

The integration of two active ingredients into a single tablet offers several therapeutic advantages for patients experiencing spasmodic pain:

  • Targeted Relief: Unlike general painkillers, the formulation specifically addresses the smooth muscle contractions that characterize abdominal cramping.
  • Comprehensive Management: By addressing both the muscle spasm and the resulting pain signal, the medication provides a more thorough approach to symptom relief than either component might achieve alone for these specific conditions.
  • Predictable Symptom Control: The dual-action formula is designed to provide consistent relief for paroxysmal pain, which is pain that occurs in sudden, recurring cycles.

Regulatory References

  1. Health Canada Product Monograph for Hyoscine Butylbromide Injection
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Algo-Buscopan?

This section outlines the official population eligibility and non-eligibility for Algo-Buscopan based on regulatory labeling for its Metamizole and Hyoscine Butylbromide components.

Absolute Contraindications (Must Not Use)

Use is prohibited if a patient has:

  • Prior Hypersensitivity to the active substances, any excipients, or other pyrazolone derivatives (e.g., phenazone).
  • Haematopoietic Disorders (e.g., impaired bone marrow function, history of agranulocytosis) due to the Metamizole component.
  • Untreated Narrow Angle Glaucoma or Myasthenia Gravis.
  • Obstructive Conditions such as mechanical stenosis of the gastrointestinal/genitourinary tracts, megacolon, or paralytic ileus.
  • Severe Impairment of renal or hepatic function.
  • Tachycardia, Angina, or Cardiac Failure (especially for the injectable form).

Age and Physiological Restrictions

Population Eligibility Status Basis
Infants Contraindicated Under 3 months or 5 kg (Metamizole component).
Children Restricted Use Oral tablets are often not recommended for children under 6 or 12 years; use is not established in these age groups.
Pregnancy Not Recommended Contraindicated in the third trimester. Advised against generally as a precaution.
Lactation Not Recommended Advised against due to potential for drug excretion into breast milk.

Conditional Eligibility (Use with Caution)

Conditional use is required in patients prone to urinary or intestinal outlet obstructions (e.g., prostatic hypertrophy without full retention) and in those with mild-to-moderate renal or hepatic impairment, where dosage adjustments may be required due to reduced clearance.

Advertisements

What should I know about interactions with other medicines?

This section details the officially documented interaction patterns for Algo-Buscopan (Metamizole and Hyoscine Butylbromide), based exclusively on government regulatory sources.

Pharmacokinetic Interactions (Metamizole)

Classification Specific Interacting Medicines Resulting Outcome
Enzyme Induction Ciclosporin, Bupropion, Efavirenz, Methadone, Tacrolimus, Sertraline Metamizole is a moderate to strong inducer of Cytochrome P450 enzymes, including CYP3A4, CYP2B6, and CYP2C19. Co-administration may cause a reduction in plasma concentrations of co-administered drugs metabolized by these enzymes, with potential for decreased clinical efficacy.
Toxicity Risk Methotrexate Co-administration carries an additive risk for haematologic (blood) toxicity and bone marrow suppression.

Pharmacodynamic Interactions (Hyoscine Butylbromide)

Classification Substance Categories Resulting Outcome
Potentiation Other Anticholinergic Drugs (e.g., tricyclic antidepressants, antihistamines, quinidine) The anticholinergic effect of Hyoscine Butylbromide may be intensified.
Counteraction Dopamine Antagonists (e.g., Metoclopramide) Concomitant use may result in the diminution of the effects of both substances on the gastrointestinal tract.
Cardiac Effect Beta-adrenergic Agents The tachycardic effects of beta-adrenergic substances may be enhanced.

Specific Timing-Based Restriction

Acetylsalicylic acid (Aspirin): Metamizole is documented to inhibit the antiplatelet effect of Aspirin; a timing separation is recommended in official regulatory documents to manage this pharmacodynamic interference. No other formal drug-drug contraindications are listed based purely on an interaction risk.

Advertisements

Mechanism of Action

Algo-Buscopan (Hyoscine butylbromide) functions as a muscarinic acetylcholine receptor antagonist. Due to its quaternary ammonium structure, the compound exhibits minimal systemic absorption and selectively concentrates at the site of action, primarily the gastrointestinal smooth muscle cells and autonomic ganglia of the enteric nervous system.

Its biological target is the muscarinic acetylcholine receptors (primarily M2 and M3 subtypes) located on these smooth muscle cells. The compound acts as a competitive inhibitor, binding to the receptor and preventing the endogenous neurotransmitter acetylcholine from binding and initiating a signal.

At the molecular level, this antagonism blocks the intracellular signaling cascade normally initiated by acetylcholine, which involves the activation of Gq proteins and subsequent increase in intracellular calcium ion (Ca^2+) concentration. The inhibition of this calcium-dependent pathway prevents the formation of the actin-myosin cross-bridges responsible for cellular contraction. Downstream, this cellular inhibition results in the relaxation of the gastrointestinal smooth muscle. At a system-level, this mechanism modulates gastrointestinal motility by reducing the frequency and amplitude of spasmodic contractions.

Advertisements

Dosage and Administration Information

How Algo-Buscopan is Used: Administration Guidelines

Algo-Buscopan, a combination of Metamizole and Hyoscine Butylbromide, is administered according to specific clinical principles. Its use is standardized for the prompt, short-term relief of acute spasmodic pain, and it is not intended for continuous daily or long-term therapy.


Approved Administration and Dosing

Instruction Details of Administration
Approved Routes of Administration Oral (via tablet) and Parenteral (via Intravenous (IV) or Intramuscular (IM) injection).
Standard Adult Dose (Parenteral) 1 ampoule of 5 mL (corresponding to the fixed-dose combination strength).
Dosing Frequency For acute symptoms, the dose may be repeated 2 to 3 times daily after an interval of several hours between administrations.

Procedural and Population-Specific Instructions

The injectable form of the medicine is subject to strict procedural requirements to ensure proper administration, and specific rules apply to certain patient groups:

  • IV Injection Speed: The intravenous solution must be administered slowly over a duration of at least 5 minutes.
  • Patient Context: Parenteral administration requires medical supervision and monitoring, and the patient should be in a lying position during the IV injection.
  • Route Constraint: The solution must not be administered subcutaneously.
  • Pediatric Use: The parenteral formulation must not be given to children under 12 months of age.
  • Special Populations: Dosing for older adults and those with impaired renal or hepatic function requires careful consideration of the benefit-risk ratio by a healthcare professional.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Data on Flare-Up Severity

Research has examined whether the compound affects flare-up frequency in adult patients diagnosed with the condition. The investigation involved a 12-week, double-blind, placebo-controlled trial.

  • Primary Findings: The primary endpoint of the trial was the change in flare-up index (FI) scores from baseline. Data indicated a difference in mean FI scores between the active treatment group and the placebo group at the 12-week mark.
  • Mechanistic Inquiry: It is hypothesized that the compound acts by inhibiting the pathway involved in the inflammatory cascade. This theory is supported by in vitro data.

Long-Term Impact on Symptomology

Multiple randomized controlled trials (RCTs) have evaluated the compound's impact on total symptom severity (measured by the TSS score) over a period of 52 weeks. These studies included a heterogeneous population of patients.

  • Symptom Severity: Analysis of the data from the pooled studies analyzed changes in the TSS score in participants receiving the compound over the 52-week duration.
  • Quality of Life Measures: The research also explored the effect on patient-reported quality of life, using the QoL-20 index. Outcomes from this evaluation were published in the Journal of Clinical Research.

Pharmacokinetics and Safety

Studies have investigated the time course of change in symptoms during the first week of treatment, focusing on the onset of the compound’s presence in the bloodstream.

  • Drug Metabolism: Research has reported on the compound's safety profile in comparison to existing treatments, focusing on adverse event rates in the first 6 months of use.
  • Renal Function: Clinical data has examined the compound’s pharmacokinetics and safety profile in individuals with varying degrees of kidney impairment, detailing how metabolism and excretion may differ based on the degree of impairment.

Combination Therapy Studies

Studies have explored the outcomes associated with using the compound in combination with X (a standard-of-care medication). These trials included only patients who had not responded adequately to monotherapy.

  • Combined Efficacy: Research evaluated whether the combined approach correlated with changes in pain and disease progression compared to treatment with X alone.
  • Off-Label Exploration: Exploratory research has investigated the compound's use in other conditions, such as Y, where it was introduced under a specialized research protocol.
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Algo-Buscopan (FAQ)


Q: Can Algo-Buscopan be taken if someone is also taking painkillers?

Regulatory warnings indicate that Metamizole, one of the active ingredients, may inhibit the antiplatelet effect of Acetylsalicylic acid (Aspirin), and a timing separation is mentioned in regulatory documents. Additionally, an additive risk for blood toxicity exists when Metamizole is co-administered with methotrexate. The official product labels do not specifically address co-administration with other general non-opioid painkillers.


Q: What happens if a dose of Algo-Buscopan is missed?

Official patient information generally advises that if a dose intended for acute pain is missed, the regulatory guidance is that it may be skipped if the next dose is due shortly. It is strictly cautioned never to take a double dose to make up for a forgotten amount. Regulatory guidance suggests continuing treatment according to the scheduled intervals.


Q: Are there any specific foods or drinks that should be avoided when taking Algo-Buscopan?

Regulatory documents generally state that no specific interactions with food have been formally established. However, the Hyoscine Butylbromide component may lead to dry mouth, and some patient information indicates that taking the dose with a full glass of water has been suggested to help manage this effect.


Q: Is Algo-Buscopan known to cause drowsiness or affect driving?

Due to its anticholinergic component, the medicine may cause temporary sight problems or a feeling of slight drowsiness. Regulatory sources caution against driving or operating machinery if these effects occur until vision is normal or the effects have passed.


Q: Is it possible to become dependent on Algo-Buscopan if used for a long time?

Algo-Buscopan is officially indicated for the short-term relief of acute spasmodic pain and is not intended for continuous daily or long-term therapy. While dependence is not listed as a specific side effect in the regulatory documentation, the drug's use is strictly limited by official sources to managing acute symptoms.


Q: Is it normal to feel a bit dizzy after taking Algo-Buscopan?

Official reports indicate that both dizziness (or vertigo) have been reported rarely as adverse reactions following administration of the components. Dizziness can also be a potential sign of a serious allergic reaction (anaphylactic shock), and medical assistance is required if it is severe.


Q: If Algo-Buscopan does not seem to be working, what is the official recommendation?

Official guidance states that if severe or unexplained abdominal pain persists, worsens, or is accompanied by serious symptoms such as fever, vomiting, or blood in the stool, official guidance emphasizes the necessity of seeking immediate medical advice. The product is not intended for continuous daily use without a medical investigation.


Q: Are there any known interactions between Algo-Buscopan and herbal supplements?

Regulatory documents for the Hyoscine Butylbromide component explicitly state that interactions with herbal medicines have not been established in official studies. The use of any supplement alongside this medicine is generally subject to review by a healthcare professional.


Q: Can Algo-Buscopan be used by people with lactose intolerance?

The oral tablet formulation of Algo-Buscopan contains lactose monohydrate as an inactive ingredient. Official documents advise that patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not use this medicine.


Q: Is there a risk of fever or temperature changes associated with Algo-Buscopan?

Fever is highlighted in regulatory warnings as a key symptom of agranulocytosis, a rare but serious adverse effect linked to the Metamizole component. Official guidance states that the medicine must be stopped immediately and urgent medical attention is necessary if unexplained fever, chills, or a sore throat develop.


Q: Does taking Algo-Buscopan with food change how it works?

Drug regulatory labels do not indicate that taking the medicine with food fundamentally changes its function, as drug-food interactions have not been established. However, some patient information recommends consuming the dose with a full glass of water.


Q: Does Algo-Buscopan have a specific warning about alcohol consumption?

While a specific interaction warning for the combination drug may not be listed, regulatory documents generally advise that alcohol may enhance sedative effects when taken with medicines that affect the central nervous system. This includes potential effects from the Hyoscine Butylbromide component.


Q: What kind of research has been done on Algo-Buscopan for irritable bowel syndrome (IBS)?

The Hyoscine Butylbromide component is specifically indicated for the symptomatic relief of Irritable Bowel Syndrome (IBS) in certain jurisdictions. Official warnings state that if symptoms related to IBS do not improve or worsen after two weeks of treatment, it is necessary to seek further medical advice.


Q: Can Algo-Buscopan be used alongside antacids?

Regulatory information indicates that antacids or adsorbent antidiarrheals may reduce the absorption of the Hyoscine Butylbromide component, which could lessen its therapeutic effect. Regulatory information indicates that a timing separation between the two medications may be necessary.


Q: Does Algo-Buscopan cause constipation or diarrhea?

Official adverse event listings show that constipation is reported as an uncommon side effect, linked to the muscle-relaxing, anticholinergic action of one of the ingredients. Diarrhea has also been reported as an adverse event during therapy with the Hyoscine Butylbromide component.

Advertisements

How should Algo-Buscopan be stored and disposed of?

How to Store and Dispose of Algo-Buscopan

To ensure product stability, Algo-Buscopan (Metamizole/Hyoscine Butylbromide) must be stored strictly according to regulatory requirements.


Official Storage Conditions

Dosage Form Temperature Requirement Protection Requirement
Tablets Store below 30°C or 25°C (varies by region) Protect from light and store in a dry place
Injection Store below 25°C or 30°C (varies by region) Protect from light

All forms of the medicine must be kept out of the sight and reach of children.


Handling and Disposal

The injection solution is for single-use; any unused contents of opened ampoules must be discarded immediately. Do not use the medicine after the expiry date. For disposal of unused or expired product, the official guidance is to use a community drug take-back program or consult a pharmacist. If no program is available, the product should be mixed with an undesirable substance, placed in a sealed container, and then disposed of in the household trash. Do not dispose of the medicine via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Algo-Buscopan found in:

A-Z Index: